glp-1 shortage The impact of receptor agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic GLP-1 Drugs Driving Protein Demand

Is Compounded Tirzepatide Safe

doi: 10.1136/jnnp.54.5.388 17

It is FDA-approved, widely available, and produces roughly 30-50% more weight loss than semaglutide in clinical trials

And our current thinking is that if someone's developing obesity, particularly moderate to severe obesity in this society, they most likely have a genetic predisposition from our ancestors to put on calories and they don't balance their body fat very well

11,13 This led to the identification of two gut hormones that produce the incretin effect: glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) which are produced by L and K cells of the gut, respectively